AMP-activated protein kinase alpha 2 deletion induces VSMC phenotypic switching and reduces features of atherosclerotic plaque stability

Circulation Research

Volumn 119, Issue 6, 2016, Pages 718-730

  Ding, Ye ^a   Zhang, Miao ^b   Zhang, Wencheng ^c   Lu, Qiulun ^a   Cai, Zhejun ^a   Song, Ping ^a   Okon, Imoh Sunday ^a   Xiao, Lei ^a   Zou, Ming Hui ^a  

^a GEORGIA STATE UNIVERSITY   (United States)

^b UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^c SHANDONG UNIVERSITY   (China)

Author keywords

AMP activated protein kinases; atherosclerosis

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; AMP ACTIVATED PROTEIN KINASE ALPHA 2; CALPONIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; KRUPPEL LIKE FACTOR 4; MYOSIN HEAVY CHAIN; OSTEOPONTIN; PRAVASTATIN; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR RELA; UNCLASSIFIED DRUG; VIMENTIN; AMPK ALPHA2 SUBUNIT, MOUSE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AORTIC SMOOTH MUSCLE CELL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; ATHEROSCLEROTIC PLAQUE; BRACHIOCEPHALIC TRUNK; CELL ISOLATION; CLINICAL FEATURE; CONTROLLED STUDY; ENZYME ACTIVATION; EVALUATION STUDY; GENE DELETION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LOSS OF FUNCTION MUTATION; MACROPHAGE; MALE; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; UPREGULATION; VASCULAR SMOOTH MUSCLE CELL; WESTERN DIET; ADVERSE EFFECTS; ANIMAL; C57BL MOUSE; DEFICIENCY; GENETICS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; SMOOTH MUSCLE CELL; VASCULAR SMOOTH MUSCLE;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; DIET, WESTERN; GENE DELETION; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; PHENOTYPE; PLAQUE, ATHEROSCLEROTIC;

EID: 84980047812     PISSN: 00097330     EISSN: 15244571     Source Type: Journal    
DOI: 10.1161/CIRCRESAHA.116.308689     Document Type: Article

References (54)

1. Lusis AJ, Atherosclerosis. Nature 2000 407 233 241. doi: 10.1038/35025203
2. Hansson GK, Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005 352 1685 1695. doi: 10.1056/NEJMra043430
3. Ylä-Herttuala S, Bentzon JF, Daemen M, Stabilisation of atherosclerotic plaques. Position paper of the European Society of Cardiology (ESC) Working Group on atherosclerosis and vascular biology. Thromb Haemost 2011 106 1 19. doi: 10.1160/TH10-12-0784
4. Rzucidlo EM, Martin KA, Powell RJ, Regulation of vascular smooth muscle cell differentiation. J Vasc Surg 2007 45 suppl A A25 A32. doi: 10.1016/j.jvs.2007.03.001
5. Bennett MR, Apoptosis of vascular smooth muscle cells in vascular remodelling and atherosclerotic plaque rupture. Cardiovasc Res 1999 41 361 368
6. Clarke M, Bennett M, Defining the role of vascular smooth muscle cell apoptosis in atherosclerosis. Cell Cycle 2006 5 2329 2331. doi: 10.4161/cc.5.20.3383
7. Clarke MC, Figg N, Maguire JJ, Davenport AP, Goddard M, Littlewood TD, Bennett MR, Apoptosis of vascular smooth muscle cells induces features of plaque vulnerability in atherosclerosis. Nat Med 2006 12 1075 1080. doi: 10.1038/nm1459
8. Shankman LS, Gomez D, Cherepanova OA, Salmon M, Alencar GF, Haskins RM, Swiatlowska P, Newman AA, Greene ES, Straub AC, Isakson B, Randolph GJ, Owens GK, KLF4-dependent phenotypic modulation of smooth muscle cells has a key role in atherosclerotic plaque pathogenesis. Nat Med 2015 21 628 637. doi: 10.1038/nm.3866
9. Davies SP, Hawley SA, Woods A, Carling D, Haystead TA, Hardie DG, Purification of the AMP-Activated protein kinase on ATP-gamma-sepharose and analysis of its subunit structure. Eur J Biochem 1994 223 351 357
10. Mitchelhill KI, Stapleton D, Gao G, House C, Michell B, Katsis F, Witters LA, Kemp BE, Mammalian AMP-Activated protein kinase shares structural and functional homology with the catalytic domain of yeast Snf1 protein kinase. J Biol Chem 1994 269 2361 2364
11. Gao G, Fernandez CS, Stapleton D, Auster AS, Widmer J, Dyck JR, Kemp BE, Witters LA, Non-catalytic beta-And gamma-subunit isoforms of the 5'-AMP-Activated protein kinase. J Biol Chem 1996 271 8675 8681
12. Stapleton D, Mitchelhill KI, Gao G, Widmer J, Michell BJ, Teh T, House CM, Fernandez CS, Cox T, Witters LA, Kemp BE, Mammalian AMP-Activated protein kinase subfamily. J Biol Chem 1996 271 611 614
13. Viollet B, Horman S, Leclerc J, Lantier L, Foretz M, Billaud M, Giri S, Andreelli F, AMPK inhibition in health and disease. Crit Rev Biochem Mol Biol 2010 45 276 295. doi: 10.3109/10409238.2010.488215
14. Braco JT, Gillespie EL, Alberto GE, Brenman JE, Johnson EC, Energy-dependent modulation of glucagon-like signaling in Drosophila via the AMP-Activated protein kinase. Genetics 2012 192 457 466. doi: 10.1534/genetics.112.143610
15. Li Y, Xu S, Mihaylova MM, AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab 2011 13 376 388. doi: 10.1016/j.cmet.2011.03.009
16. Motoshima H, Goldstein BJ, Igata M, Araki E, AMPK and cell proliferation-AMPK as a therapeutic target for atherosclerosis and cancer. J Physiol 2006 574 63 71. doi: 10.1113/jphysiol.2006.108324
17. Dong Y, Zhang M, Liang B, Xie Z, Zhao Z, Asfa S, Choi HC, Zou MH, Reduction of AMP-Activated protein kinase alpha2 increases endoplasmic reticulum stress and atherosclerosis in vivo. Circulation 2010 121 792 803. doi: 10.1161/CIRCULATIONAHA.109.900928
18. Wang S, Zhang M, Liang B, Xu J, Xie Z, Liu C, Viollet B, Yan D, Zou MH, AMPKalpha2 deletion causes aberrant expression and activation of NAD(P)H oxidase and consequent endothelial dysfunction in vivo: role of 26S proteasomes. Circ Res 2010 106 1117 1128. doi: 10.1161/CIRCRESAHA.109.212530
19. Song P, Wang S, He C, Wang S, Liang B, Viollet B, Zou MH, AMPKα2 deletion exacerbates neointima formation by upregulating Skp2 in vascular smooth muscle cells. Circ Res 2011 109 1230 1239. doi: 10.1161/CIRCRESAHA.111.250423
20. Song P, Zhou Y, Coughlan KA, Dai X, Xu H, Viollet B, Zou MH, Adenosine monophosphate-Activated protein kinase-α2 deficiency promotes vascular smooth muscle cell migration via S-phase kinase-Associated protein 2 upregulation and E-cadherin downregulation. Arterioscler Thromb Vasc Biol 2013 33 2800 2809. doi: 10.1161/ATVBAHA.113.301869
21. Takaya N, Yuan C, Chu B, Saam T, Polissar NL, Jarvik GP, Isaac C, McDonough J, Natiello C, Small R, Ferguson MS, Hatsukami TS, Presence of intraplaque hemorrhage stimulates progression of carotid atherosclerotic plaques: a high-resolution magnetic resonance imaging study. Circulation 2005 111 2768 2775. doi: 10.1161/CIRCULATIONAHA.104.504167
22. Kolodgie FD, Gold HK, Burke AP, Fowler DR, Kruth HS, Weber DK, Farb A, Guerrero LJ, Hayase M, Kutys R, Narula J, Finn AV, Virmani R, Intraplaque hemorrhage and progression of coronary atheroma. N Engl J Med 2003 349 2316 2325. doi: 10.1056/NEJMoa035655
23. Jackson CL, Bennett MR, Biessen EA, Johnson JL, Krams R, Assessment of unstable atherosclerosis in mice. Arterioscler Thromb Vasc Biol 2007 27 714 720. doi: 10.1161/01.ATV.0000261873.86623.e1
24. Burke AP, Kolodgie FD, Farb A, Weber DK, Malcom GT, Smialek J, Virmani R, Healed plaque ruptures and sudden coronary death: evidence that subclinical rupture has a role in plaque progression. Circulation 2001 103 934 940
25. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R, Concept of vulnerable/unstable plaque. Arterioscler Thromb Vasc Biol 2010 30 1282 1292. doi: 10.1161/ATVBAHA.108.179739
26. Neumeister V, Scheibe M, Lattke P, Jaross W, Determination of the cholesterol-collagen ratio of arterial atherosclerotic plaques using near infrared spectroscopy as a possible measure of plaque stability. Atherosclerosis 2002 165 251 257
27. Crisby M, Nordin-Fredriksson G, Shah PK, Yano J, Zhu J, Nilsson J, Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001 103 926 933
28. Davies MJ, Richardson PD, Woolf N, Katz DR, Mann J, Risk of thrombosis in human atherosclerotic plaques: role of extracellular lipid, macrophage, and smooth muscle cell content. Br Heart J 1993 69 377 381
29. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT, Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996 7 330 335
30. Michel JB, Virmani R, Arbustini E, Pasterkamp G, Intraplaque haemorrhages as the trigger of plaque vulnerability. Eur Heart J 2011 32 1977 85, 1985a, 1985b, 1985c. doi: 10.1093/eurheartj/ehr054
31. Mann J, Davies MJ, Mechanisms of progression in native coronary artery disease: role of healed plaque disruption. Heart 1999 82 265 268
32. Johnson J, Carson K, Williams H, Karanam S, Newby A, Angelini G, George S, Jackson C, Plaque rupture after short periods of fat feeding in the apolipoprotein E-knockout mouse: model characterization and effects of pravastatin treatment. Circulation 2005 111 1422 1430. doi: 10.1161/01.CIR.0000158435.98035.8D
33. Virmani R, Burke AP, Kolodgie FD, Farb A, Vulnerable plaque: the pathology of unstable coronary lesions. J Interv Cardiol 2002 15 439 446
34. Ylä-Herttuala S, Bentzon JF, Daemen M, ESC Working Group of Atherosclerosis and Vascular Biology Stabilization of atherosclerotic plaques: an update. Eur Heart J 2013 34 3251 3258. doi: 10.1093/eurheartj/eht301
35. Salabei JK, Cummins TD, Singh M, Jones SP, Bhatnagar A, Hill BG, PDGF-mediated autophagy regulates vascular smooth muscle cell phenotype and resistance to oxidative stress. Biochem J 2013 451 375 388. doi: 10.1042/BJ20121344
36. El-Karim EA, Hagos EG, Ghaleb AM, Yu B, Yang VW, Krüppel-like factor 4 regulates genetic stability in mouse embryonic fibroblasts. Mol Cancer 2013 12 89. doi: 10.1186/1476-4598-12-89
37. Choi HC, Song P, Xie Z, Wu Y, Xu J, Zhang M, Dong Y, Wang S, Lau K, Zou MH, Reactive nitrogen species is required for the activation of the AMP-Activated protein kinase by statin in vivo. J Biol Chem 2008 283 20186 20197. doi: 10.1074/jbc.M803020200
38. Hwang JT, Ha J, Park OJ, Combination of 5-fluorouracil and genistein induces apoptosis synergistically in chemo-resistant cancer cells through the modulation of AMPK and COX-2 signaling pathways. Biochem Biophys Res Commun 2005 332 433 440. doi: 10.1016/j.bbrc.2005.04.143
39. Leverve XM, Guigas B, Detaille D, Batandier C, Koceir EA, Chauvin C, Fontaine E, Wiernsperger NF, Mitochondrial metabolism and type-2 diabetes: a specific target of metformin. Diabetes Metab 2003 29 6S88 6S94
40. Shirwany NA, Zou MH, AMPK in cardiovascular health and disease. Acta Pharmacol Sin 2010 31 1075 1084. doi: 10.1038/aps.2010.139
41. Yan FF, Liu YF, Liu Y, Zhao YX, KLF4: a novel target for the treatment of atherosclerosis. Med Hypotheses 2008 70 845 847. doi: 10.1016/j.mehy.2007.07.031
42. Zheng X, Li A, Zhao L, Zhou T, Shen Q, Cui Q, Qin X, Key role of microRNA-15a in the KLF4 suppressions of proliferation and angiogenesis in endothelial and vascular smooth muscle cells. Biochem Biophys Res Commun 2013 437 625 631. doi: 10.1016/j.bbrc.2013.07.017
43. Sharma N, Lu Y, Zhou G, Liao X, Kapil P, Anand P, Mahabeleshwar GH, Stamler JS, Jain MK, Myeloid Krüppel-like factor 4 deficiency augments atherogenesis in ApoE-/-mice-brief report. Arterioscler Thromb Vasc Biol 2012 32 2836 2838. doi: 10.1161/ATVBAHA.112.300471
44. Li HX, Han M, Bernier M, Zheng B, Sun SG, Su M, Zhang R, Fu JR, Wen JK, Krüppel-like factor 4 promotes differentiation by transforming growth factor-beta receptor-mediated Smad and p38 MAPK signaling in vascular smooth muscle cells. J Biol Chem 2010 285 17846 17856. doi: 10.1074/jbc.M109.076992
45. Evans PM, Zhang W, Chen X, Yang J, Bhakat KK, Liu C, Kruppel-like factor 4 is acetylated by p300 and regulates gene transcription via modulation of histone acetylation. J Biol Chem 2007 282 33994 34002. doi: 10.1074/jbc.M701847200
46. Tahmasebi S, Ghorbani M, Savage P, Yan K, Gocevski G, Xiao L, You L, Yang XJ, Sumoylation of Krüppel-like factor 4 inhibits pluripotency induction but promotes adipocyte differentiation. J Biol Chem 2013 288 12791 12804. doi: 10.1074/jbc.M113.465443
47. Mack CP, Signaling mechanisms that regulate smooth muscle cell differentiation. Arterioscler Thromb Vasc Biol 2011 31 1495 1505. doi: 10.1161/ATVBAHA.110.221135
48. Spin JM, Maegdefessel L, Tsao PS, Vascular smooth muscle cell phenotypic plasticity: focus on chromatin remodelling. Cardiovasc Res 2012 95 147 155. doi: 10.1093/cvr/cvs098
49. Jain MK, Ridker PM, Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005 4 977 987. doi: 10.1038/nrd1901
50. Sharyo S, Yokota-Ikeda N, Mori M, Kumagai K, Uchida K, Ito K, Burne-Taney MJ, Rabb H, Ikeda M, Pravastatin improves renal ischemia-reperfusion injury by inhibiting the mevalonate pathway. Kidney Int 2008 74 577 584. doi: 10.1038/ki.2008.210
51. McLoughlin D, McGuinness J, Byrne J, Terzo E, Huuskonen V, McAllister H, Black A, Kearney S, Kay E, Hill AD, Dietz HC, Redmond JM, Pravastatin reduces Marfan aortic dilation. Circulation 2011 124 S168 S173. doi: 10.1161/CIRCULATIONAHA.110.012187
52. Watanabe K, Sugiyama S, Kugiyama K, Honda O, Fukushima H, Koga H, Horibata Y, Hirai T, Sakamoto T, Yoshimura M, Yamashita Y, Ogawa H, Stabilization of carotid atheroma assessed by quantitative ultrasound analysis in nonhypercholesterolemic patients with coronary artery disease. J Am Coll Cardiol 2005 46 2022 2030. doi: 10.1016/j.jacc.2005.04.070
53. Libby P, Collagenases and cracks in the plaque. J Clin Invest 2013 123 3201 3203. doi: 10.1172/JCI67526
54. Sun W, Lee TS, Zhu M, Gu C, Wang Y, Zhu Y, Shyy JY, Statins activate AMP-Activated protein kinase in vitro and in vivo. Circulation 2006 114 2655 2662. doi: 10.1161/CIRCULATIONAHA.106.630194